Related Experiment Video

Updated: May 28, 2026

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia

Jan A Burger, Julia Hoellenriegel

    Oncotarget
    |October 19, 2011
    PubMed

    Insights

    Phosphoinositide 3-kinase (PI3K) signaling is a new target for B cell malignancies. This approach is being tested in clinical trials for Chronic Lymphocytic Leukemia (CLL).

    Area of Science:

    • Oncology
    • Molecular Biology
    • Hematology

    Background:

    • Chronic Lymphocytic Leukemia (CLL) is a B cell malignancy.
    • Phosphoinositide 3-kinase (PI3K) signaling pathways are crucial in B cell development and function.
    • Dysregulation of PI3K signaling is implicated in the pathogenesis of various B cell malignancies.

    Discussion:

    • Targeting PI3K signaling represents a novel therapeutic strategy for B cell malignancies.
    • Early clinical trials are investigating PI3K inhibitors in patients with CLL.
    • This approach signifies a shift towards molecularly targeted therapies in hematologic cancers.

    Key Insights:

    • PI3K signaling pathways are actively being explored as therapeutic targets in B cell malignancies.
    • Clinical trials are underway to evaluate the efficacy of PI3K inhibitors in Chronic Lymphocytic Leukemia.
    • The development of PI3K-targeted therapies marks a significant advancement in precision medicine for hematologic cancers.

    Outlook:

    • Further research is needed to optimize PI3K-targeted therapies for B cell malignancies.
    • Combination strategies involving PI3K inhibitors may enhance treatment outcomes.
    • Successful clinical development could lead to new standard-of-care options for patients with CLL and other B cell cancers.

    More Related Videos

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

    Published on: July 17, 2020

    Related Concept Videos

    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
    Amplifying Signals via Enzymatic Cascade01:22

    Amplifying Signals via Enzymatic Cascade

    When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
    The Intrinsic Apoptotic Pathway01:31

    The Intrinsic Apoptotic Pathway

    Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
    IP3/DAG Signaling Pathway01:11

    IP3/DAG Signaling Pathway

    Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
    Phosphoinositides and PIPs01:42

    Phosphoinositides and PIPs

    Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
    Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...